Why US Biotech Companies Choose UK CROs
For US biotech companies planning clinical trials in Europe, partnering with a UK-based CRO offers distinct advantages:
- EMA Regulatory Expertise: Navigate European Medicines Agency requirements with a team experienced in EU regulatory submissions, scientific advice procedures, and marketing authorisation applications
- Access to European Investigator Sites: Leverage established relationships with clinical sites across the UK and EU, accelerating site selection and patient recruitment
- FDA + EMA Alignment: Design studies that satisfy both FDA and EMA requirements, supporting global development strategies and avoiding costly protocol amendments
- Time Zone Coverage: Maintain continuous progress on your programme with a UK team working while your US office is offline
- Cost-Effective Trial Delivery: Competitive site costs and operational efficiencies without compromising on quality or regulatory compliance
